Redeye: Ependion: Stable quarter, albeit the mixed picture remains
Redeye updates its estimates after Ependion’s Q3 2023 report, which came in close to our forecasts, not least on the sales side. Meanwhile, margins were somewhat better than expected. Although Ependion reported strong sales and a record EBIT, there are a few question marks regarding the order intake and how a potentially weaker industrial cycle, not least in Asia, might impact the near-term estimates.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/